Cleary Gottlieb represented Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. Incorporated and UBS Securities LLC as the underwriters of 10 million common shares of Vertex Pharmaceuticals Incorporated. The transaction priced on September 14, 2006 and closed on September 20, 2006.
Vertex is a biotechnology company engaged in the discovery and development of breakthrough small molecule drugs. Vertex co-discovered the HIV protease inhibitor Lexiva. Its product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection.